TSN084

DRUG2 trials

Sponsors

Tyligand Bioscience (Shanghai) Limited

Conditions

Cancer (With or Without Metastasis)Malignant Neoplasm

Phase 1

Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.

Active, not recruitingNCT05300438

Tyligand Bioscience (Shanghai) LimitedCancer (With or Without Metastasis)

Start: 2022-02-18End: 2025-06-30Target: 74Updated: 2024-06-25

TSN084 Treating Patients With Advanced Malignant Tumors

RecruitingNCT06386705

Tyligand Bioscience (Shanghai) LimitedMalignant Neoplasm

Start: 2022-07-20End: 2026-06-30Target: 114Updated: 2024-07-29

Related Papers

Abstract 4027: TSN084, a multi-kinase inhibitor, overcomes acquired drug-resistant mutations of cMet, Trks, and Flt3, and displays broad activities against kinase oncotargets Axl, DDRs, and CDK8/19

Cancer Research2023-04-042 citations